Skip to content
value.today

Kleo Pharmaceuticals, Inc.

🇺🇸 New Haven, Connecticut, USAPharmaceuticalsFounded 2015
Total raised
$54 M
3 rounds on record
Latest round
$21 M
Nov 2018
First round on record
Aug 2016
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Kleo Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2018$21 MNo. 3$10 to $50 million

Kleo Pharmaceuticals, Inc.: Raise no. 3, Nov 2018

Investors in this round

19 investors had bought by the notice of Jan 15, 2019: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$21 M of $21 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Douglas Manion · Executive Officer, Director
  • Roy Prieb · Executive Officer, Director
  • Alexander Goor · Director
  • Charles G. Drake · Director
  • Declan Doogan · Director
  • John W. Childs · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Roy Prieb, Chief Operating Officer, Chief Financial Officer, Secretary. Source: SEC Form D, newest notice filed Jan 15, 2019. Read the notice at the SEC.

equitySEC
Feb 2017$19 MNo. 2$10 to $50 million

Kleo Pharmaceuticals, Inc.: Raise no. 2, Feb 2017

Investors in this round

23 investors had bought by the notice of May 23, 2017: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$19 M (amount offered: indefinite)
Smallest investment taken
$2,500
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Spiegel · Executive Officer, Director
  • Roy Prieb · Executive Officer, Director
  • Charles G. Drake · Director
  • Declan Doogan · Director
  • John W. Childs · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Spiegel, Chief Executive Officer. Source: SEC Form D, newest notice filed May 23, 2017. Read the notice at the SEC.

equitySEC
Aug 2016$14 MNo. 1$10 to $50 million

Kleo Pharmaceuticals, Inc.: Raise no. 1, Aug 2016

Investors in this round

11 investors had bought by the notice of May 29, 2018: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Spiegel · Executive Officer, Director
  • Douglas G. Manion · Executive Officer
  • Roy Prieb · Executive Officer, Director
  • Charles G. Drake · Director
  • Declan Doogan · Director
  • John W. Childs · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Roy Prieb, Cfo/coo. Source: SEC Form D and 1 amendment, newest notice filed May 29, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Kleo Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2019).

    SEC Form D · Jan 2019

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2019

That is all the official record says: Kleo Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Kleo Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 23 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Kleo Pharmaceuticals, Inc.
NameRoleNamed in
Douglas ManionExecutive officerJan 2019
Roy PriebExecutive officerJan 2019
David SpiegelExecutive officerMay 2018
Douglas G. ManionExecutive officerMay 2018
Alexander GoorDirectorJan 2019
Charles G. DrakeDirectorJan 2019
Declan DooganDirectorJan 2019
Douglas ManionDirectorJan 2019
John W. ChildsDirectorJan 2019
Roy PriebDirectorJan 2019
David SpiegelDirectorMay 2018